New York, February 28, 2026, 15:32 EST — The market is now closed.
- AbbVie shares pushed higher Friday, gaining 3.29% to close at $232.08 and topping the broader U.S. market’s decline.
- The drugmaker is set to raise roughly $7.95 billion net through a seven-part bond sale, with settlement coming up on March 4.
- AbbVie’s general counsel offloaded 22,381 shares at $230 apiece following option exercises, a Friday filing showed.
AbbVie Inc shares jumped 3.29% to close at $232.08 on Friday, bucking a three-day slide and outperforming the wider market slump. The S&P 500 lost 0.43%, Dow shed 1.05%. AbbVie not only broke its own losing streak but also left Johnson & Johnson, Pfizer, and Amgen trailing behind.
U.S. markets closed out the week and will stay quiet until Monday, leaving investors to see whether last week’s bounce has any legs. AbbVie faces a string of balance-sheet updates in the coming days, and the margin for error in its messaging is slim.
An SEC filing from Feb. 24 outlined a multi-tranche senior notes offering, putting net proceeds after fees at roughly $7.95 billion. AbbVie said it plans to channel those funds toward paying down borrowings from a $4.0 billion 364-day delayed-draw term loan, set to mature in May 2026. That facility still has $2.0 billion outstanding. The company also flagged possible use of the cash for general corporate purposes, which could involve paying down or buying back other debt.
The pricing term sheet, dated Feb. 26, outlined seven separate tranches, starting with a $750 million floating-rate note maturing in 2028 and stretching out to fixed-rate offerings with maturities as late as 2066. Coupons ranged from 3.775% up to 5.650%. Settlement was set for March 4, a T+6 timeline, according to the document, which also confirmed ratings of A2 (stable) from Moody’s and A- (stable) from S&P.
AbbVie’s executive vice president, general counsel and secretary, Perry C. Siatis, sold off 22,381 shares at $230 apiece on Feb. 25, according to a separate Form 4 filed Friday. He exercised stock options ahead of the sale, which was carried out under a pre-set Rule 10b5-1 plan. After the transaction, Siatis was left holding 38,137 shares, the filing showed.
Equity holders aren’t eyeing the bond sale for growth; it’s really a question of funding costs, and how AbbVie times its refinancing, plus the rates it locks in.
AbbVie’s refinancing arrives as investors keep circling the same issue that’s hovered since Humira lost U.S. exclusivity: whether the company’s newer immunology offerings can maintain momentum. Earlier this month, AbbVie projected its 2026 profit would beat Wall Street’s forecasts and laid out a target—Rinvoq and Skyrizi together should deliver around $31.6 billion in sales that year.
Still, there’s a clear risk here. Should credit conditions clamp down and yields tick up, funding costs respond in a hurry—and AbbVie’s got significant capital at stake. Then there’s Rinvoq and Skyrizi. Any slip in their growth—be it due to rival drugs, squeezed pricing, or weaker demand—could put the stock’s “defensive” reputation to the test, with little to shield it.
Next up for traders: will Friday’s rally carry through to the March 2 open? AbbVie’s note deal still needs to settle on March 4, and that date is circled—any unexpected hiccup could matter. March 4 remains the key date here.
